Cargando…
Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
PURPOSE: Stromal tumor-infiltrating lymphocytes (TILs) are independent prognostic factors in systemically untreated early-stage triple-negative breast cancer (TNBC). Other immune biomarkers including CD8, CD20, programmed cell death-ligand 1 (PD-L1), and tertiary lymphoid structures (TLS) are also r...
Autores principales: | Yazaki, Shu, Shimoi, Tatsunori, Yoshida, Masayuki, Sumiyoshi-Okuma, Hitomi, Arakaki, Motoko, Saito, Ayumi, Kita, Shosuke, Yamamoto, Kasumi, Kojima, Yuki, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Noguchi, Emi, Murata, Takeshi, Shiino, Sho, Takayama, Shin, Suto, Akihiko, Ohe, Yuichiro, Fujiwara, Yasuhiro, Yonemori, Kan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823028/ https://www.ncbi.nlm.nih.gov/pubmed/36385236 http://dx.doi.org/10.1007/s10549-022-06787-x |
Ejemplares similares
-
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023) -
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
por: Watanabe, Sho, et al.
Publicado: (2023) -
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022) -
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022) -
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)